1/ 🧵 on China’s oral vaccine
#ConvideciaAir
by CanSino Inc.
that received an emergency authorization in China.
#ConvideciaAir
by CanSino Inc.
that received an emergency authorization in China.
2/ Booster vaccination with Convidecia Air (Ad5-nCoV) induced a superior T-cell response and neutralizing antibody responses compared to those induced by the homologous inactivated vaccine booster or heterologous recombinant protein vaccine booster.
3/ At day 7 after booster vaccination, intramuscular Ad5-nCoV induced an obvious IgG antibody response, but no IgG antibody response was found in the aerosolized Ad5-nCoV group, indicating that aerosolized Ad5-nCoV stimulated a slower systemic immune response .
4/ At day 14 after booster vaccination, the systemic immune advantage of aerosolized Ad5-nCoV was demonstrated. Only 1/5 of the dose given by intramuscular injection produced a T-cell immune response higher than that of intramuscular Ad5-nCoV.
5/ The neutralizing antibodies against Omicron induced by aerosolized Ad5-nCoV were higher compared to those induced by intramuscular injection.
6/ The neutralizing antibodies from most intramuscular COVID-19 vaccines peak at day 14 after booster vaccination and then decline.
7/ At day 28 after booster vaccination, the neutralizing antibodies induced by aerosolized Ad5-nCoV still tended to be increased compared to those at day 14, showing different kinetics from other intramuscular booster vaccination regimens examined.
8/ T-cell immunity is required for viral clearance and supports the generation and maintenance of high-affinity antibodies.
9/ Adenovirus-vectored COVID-19 vaccines are advantageous as they induce a strong T-cell response, and, aerosolized Ad5-nCoV at a lower dose induced a more substantial systemic IFNγ cellular response than intramuscular Ad5-nCoV.
10/ The resident cellular responses may be stronger in the airway and lung than in the blood, since a stronger cellular response in the lungs than in the spleen of mice via intranasal vaccination with Ad5-nCoV was observed.
11/ Viral mutations have a less pronounced impact on T-cell immunity than on neutralizing antibody responses, which can limit the impact of individual viral mutations and potentially enhance protection against severe disease from SARS-CoV-2 variants.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
